Sort
10,766 grants matching “checkpoint inhibitor”
Immunotherapy of prostate cancer using an anti-CD6 monoclonal antibody
$218,790David Alan Fox · University Of Michigan At Ann Arbor · R21 · FY2025 · CA
Interruption of squalene epoxidase and DNA damage response in cancer therapy
$218,790Junran Zhang · Ohio State University · R21 · FY2020 · CA
STK11 loss of function and anti-PD-1 therapy resistance in KRAS-driven lung adenocarcinoma
$218,790David Joseph Seward · University Of Vermont & St Agric College · R21 · FY2023 · CA
Engineered T cells for improved migration into solid tumor sites
$218,790Jordan Jacobelli · University Of Colorado Denver · R21 · FY2025 · CA
The Role of the Tumor Microenvironment in Resistance to Oncogenic KRAS Inhibition in Lung Cancer
$218,790Stefanie Galban · University Of Michigan At Ann Arbor · R21 · FY2024 · CA
Dietary methionine restriction as a therapeutic strategy for metastatic melanoma
$218,679Isabelle Racine Miousse · University Of Arkansas At Fayetteville · P20 · FY2022 · GM
Use of Patient-Reported Outcomes in Understanding Symptomatic Adverse Events in Early-Phase Trials of Combination Treatments that Include Immune Checkpoint Inhibitors and Targeted Therapy
$218,645Goldy C George · University Of Tx Md Anderson Can Ctr · R01 · FY2025 · CA
G2 Role For Cdk2 in Human Cells
$218,624University Of Pennsylvania · R01 · FY2004 · GM
Leveraging cancer-specific defects in nuclear integrity to inform novel synthetic lethal strategies
$218,588Charles Patrick Lusk · Yale University · R21 · FY2019 · CA
Armed oncolytic parvoviral vectors for modulating the tumor microenvironment
$218,588Peter Tattersall · Yale University · R21 · FY2020 · CA
Assessing the role of the DNA repair landscape in immune checkpoint therapy
$218,588Joann B Sweasy · Yale University · R21 · FY2017 · CA
Mechanisms of Tumor Derived Neutrophil Induced Apoptosis in Lymphocytes
$218,585A. McGarry Houghton · Fred Hutchinson Cancer Research Center · R01 · FY2021 · CA
Redefining hemophagocytic lymphohistiocytosis in hematologic malignancies
$218,538Michael Jordan · Cincinnati Childrens Hosp Med Ctr · R21 · FY2022 · CA
Ex vivo generation of tumor-reactive T cells for adoptive cell transfer using an immune enhanced, patient derived tumor organoid-on-a-chip (iTOC)
$218,513Aleksander Skardal · Ohio State University · R21 · FY2022 · CA
Project 2 - Joshua Hood, PhD
$218,400Joshua L. Hood · University Of Louisville · P20 · FY2021 · GM
GENES THAT CONTROL CELL NUMBER--GI/S CHECKPOINT
$218,225Baylor College Of Medicine · R01 · FY2002 · HL
Immune cell states in endocrine immune related adverse events (IRAEs)
$218,096Melissa G Lechner · University Of California Los Angeles · U19 · FY2024 · AI
Improving immunotherapies to melanoma through modulation of MAIT cell activation by the microbiome
$218,089Martin McCarter · University Of Colorado Denver · R21 · FY2021 · CA
Impact of Obesity on Immuno-Oncology Agents in Endometrial Cancer
$218,089Victoria Lin Bae-Jump · Univ Of North Carolina Chapel Hill · R21 · FY2022 · CA
Reversible vitamin A-dependent arrest of spermatogonia
$218,035James K Tsuruta · Univ Of North Carolina Chapel Hill · R01 · FY2007 · HD
Immunotherapy of Uveal Melanoma using PRAME Vaccine in Combination with Adoptive T Cell Therapy
$218,011Cassian Yee · University Of Tx Md Anderson Can Ctr · R01 · FY2024 · CA
Liquid Biopsy Core
$217,928Amir Goldkorn · University Of Southern California · P30 · FY2022 · CA
Identifying drug synergistic with cancer immunotherapy
$217,810Avinash Das Sahu · University Of New Mexico Health Scis Ctr · R00 · FY2024 · CA
Development of Mouse and Humanized Models to Study Sex Disparities in Tumor Progression and Treatment of NSCLC
$217,738Joseph William Landry · Virginia Commonwealth University · R21 · FY2023 · CA
Modulation of cancer induced immune suppression via inhibition of SCD1
$217,685Karen E Hayes · Modulation Therapeutics, Inc. · R44 · FY2025 · CA